Asset profile
valproate
Small molecule
Evidence outlook
Approved: Epilepsy (label: complex partial seizures, simple and complex absence seizures, and adjunctive use in multiple...)
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
62 competitors in this universe: 1 direct rival (same mechanism and indication), 1 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Valproate: this drug | Approved | Small molecule | GABAergic neurotransmission | ||
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | ||
| Divalproex Sodium (Depakote ER) | Approved | — | GABAergic neurotransmission | ||
| Brivaracetam | Approved | Small molecule | Synaptic vesicle glycoprotein 2A (SV2A) | ||
| Cannabidiol (Epidiolex) | Approved | Small molecule | GPR55 / TRPV1 / adenosine transport (multi-target), cannabinoid | ||
| Carbamazepine | Approved | Small molecule | Sodium channels | ||
| Cenobamate (Xcopri) | Approved | Small molecule | Sodium channels + GABA-A receptors | ||
| Clobazam (Onfi) | Approved | Small molecule | GABA-A receptor | ||
| Clobazam (Sympazan) | Approved | Small molecule | GABA-A receptor (benzodiazepine site) | ||
| Diastat | Approved | Combination | GABA-A receptor | ||
| Diazepam (Valium) | Approved | Small molecule | GABA-A receptor | ||
| Diazepam (Valtoco) | Approved | Small molecule | GABA-A receptor | ||
| Eslicarbazepine Acetate (Aptiom) | Approved | Small molecule | Voltage-gated sodium channel | ||
| Ethosuximide | Approved | Small molecule | T-type calcium channel | ||
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) | ||
| Ezogabine (Potiga) | Approved | Small molecule | Kv7 potassium channel |
…and 47 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2)
December 2026 (2)
What to watch
What to watch
2027 (3)
February 2027 (1)
What to watch
September 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (5)
January 2028 (1)
June 2028 (4)
What to watch
What to watch
What to watch
What to watch
2031 (1)
May 2031 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.